Skip to main content
. 2024 May 23;15:1376494. doi: 10.3389/fphar.2024.1376494

TABLE 5.

The signal strength of the top 20 AEs of fingolimod and siponimod according to death reports.

SOC PT N PRR (χ2) ROR (95% CI) IC
Fingolimod
Eye disorders Macular oedema 865 47.27 (29,986.50) 47.42 (43.93-51.17) 5.19
Infections and infestations Cryptococcal meningoencephalitis 12 32.46 (302.21) 32.46 (17.42-60.49) 4.75
Investigations CSF protein abnormal 3 22.02 (52.68) 22.02 (6.57-73.84) 4.28
Infections and infestations Neurocryptococcosis 4 21.26 (67.88) 21.26 (7.48-60.49) 4.23
Investigations Electrocardiogram PR shortened 15 19.27 (230.97) 19.27 (11.27-32.96) 4.11
Investigations CSF glucose decreased 6 19.27 (92.39) 19.27 (8.25-45.03) 4.11
Nervous system disorders Optic neuritis 684 18.44 (10,080.83) 18.49 (17.08-20.02) 4.05
Neoplasms benign, malignant and unspecified Anaplastic large cell lymphoma T- and null-cell types 13 17.13 (177.70) 17.13 (9.66-30.38) 3.96
Nervous system disorders Paraparesis 111 15.98 (1,412.17) 15.98 (13.15-19.43) 3.87
Nervous system disorders Brain stem syndrome 31 12.45 (301.93) 12.45 (8.63-17.95) 3.53
Infections and infestations JC virus infection 77 12.33 (742.09) 12.33 (9.78-15.55) 3.52
Infections and infestations Meningitis cryptococcal 73 11.93 (678.79) 11.94 (9.41-15.15) 3.48
Renal and urinary disorders Neurogenic bladder 97 11.36 (853.86) 11.37 (9.25-13.97) 3.41
Investigations CSF protein increased 25 10.28 (196.29) 10.28 (6.86-15.41) 3.28
Eye disorders Ophthalmoplegia 76 9.41 (538.45) 9.41 (7.47-11.87) 3.16
Nervous system disorders Neuromyelitis optica spectrum disorder 51 9.29 (356.01) 9.30 (7.01-12.33) 3.14
Neoplasms benign, malignant and unspecified Penile squamous cell carcinoma 3 9.07 (20.34) 9.07 (2.83-29.06) 3.11
Neoplasms benign, malignant and unspecified Squamous cell carcinoma of the cervix 8 9.00 (53.77) 9.00 (4.41-18.36) 3.10
Nervous system disorders Hemiparesis 567 7.70 (3,149.19) 7.71 (7.09-8.39) 2.88
Nervous system disorders Demyelination 118 7.52 (636.09) 7.52 (6.25-9.05) 2.85
Siponimod
Infections and infestations JC virus infection 3 5.91 (12.21) 5.91 (1.90-18.37) 2.56
Nervous system disorders Hemiparesis 33 5.68 (126.79) 5.68 (4.04-8.00) 2.50
Infections and infestations Urosepsis 12 3.84 (25.22) 3.85 (2.18-6.78) 1.94
Cardiac disorders Bradycardia 45 2.58 (43.42) 2.58 (1.93-3.46) 1.36
Nervous system disorders Paralysis 12 2.54 (11.15) 2.54 (1.44-4.47) 1.34
Infections and infestations Pyelonephritis 7 2.45 (5.98) 2.45 (1.17-5.13) 1.29
Nervous system disorders Seizure 109 1.99 (54.01) 2.00 (1.66-2.41) 0.99
Nervous system disorders Status epilepticus 7 1.92 (3.08) 1.92 (0.91-4.03) 0.94
Infections and infestations COVID-19 pneumonia 8 1.85 (3.14) 1.85 (0.93-3.71) 0.89
Vascular disorders Hypertensive crisis 7 1.79 (2.45) 1.79 (0.85-3.76) 0.84
Psychiatric disorders Hallucination 32 1.39 (3.44) 1.39 (0.98-1.96) 0.47
Renal and urinary disorders Nephrolithiasis 17 1.10 (0.15) 1.10 (0.68-1.77) 0.14
Infections and infestations Sepsis 39 1.04 (0.06) 1.04 (0.76-1.42) 0.05
Cardiac disorders Acute myocardial infarction 10 1.03 (0.01) 1.03 (0.55-1.91) 0.04
Nervous system disorders Unresponsive to stimuli 8 0.94 (0.03) 0.94 (0.47-1.88) −0.09
Nervous system disorders Cerebrovascular accident 50 0.92 (0.36) 0.92 (0.70-1.21) −0.12
Nervous system disorders Loss of consciousness 36 0.89 (0.48) 0.89 (0.64-1.24) −0.17
Nervous system disorders Cerebral infarction 7 0.86 (0.17) 0.86 (0.41-1.80) −0.22
Neoplasms benign, malignant and unspecified Breast cancer 27 0.76 (1.98) 0.76 (0.52-1.11) −0.39
Respiratory, thoracic and mediastinal disorders Acute respiratory distress syndrome 4 0.74 (0.36) 0.74 (0.28-1.97) −0.43